The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial
Objective: To assess the tolerability of opicapone (OPC) when used in elderly patients with Parkinson’s disease (PD) in real-world conditions. Background: OPC proved to be…Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data
Objective: To evaluate the efficacy and tolerability of opicapone in patients in Parkinson’s disease (PD) patients with early/simple motor fluctuations (E/S-MF) in the Spanish clinical…Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…Efficacy of opicapone according to levodopa’s duration of use in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation (MF) according to levodopa’s duration of use. Background: OPC…Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations
Objective: This post-hoc analysis evaluated the impact of 3-month earlier versus postponed initiation of opicapone (OPC) in patients with Parkinson’s disease (PD) and motor fluctuations.…Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
Objective: To evaluate opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations according to disease- and therapy-related characteristics. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis
Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 13
- Next Page »